# Risk of first–time diagnosis of Alzheimer's disease in patients with type 2 diabetes (with obesity) (comparison between matched semaglutide vs other anti–diabetes medications groups)

| Size/Group | Exposure Group | Comparison Group | Exposure Group Cases (Overall Risk) | Comparison Group Cases(Overall Risk) | | HR (95% CI) |
|---|---|---|---|---|---|---|
| 9,533 | Semaglutide | Insulin | 11 (0.12%) | 33 (0.35%) | | 0.29 (0.15–0.58) |
| 9,530 | Semaglutide | Metformin | 11 (0.12%) | 23 (0.24%) | | 0.45 (0.22–0.92) |
| 8,224 | Semaglutide | DPP–4i | 11 (0.13%) | 20 (0.24%) | | 0.50 (0.24–1.05) |
| 7,649 | Semaglutide | SGLT2i | <10 (<0.13%) | 19 (0.25%) | | 0.48 (0.22–1.03) |
| 8,867 | Semaglutide | SU | 11 (0.12%) | 33 (0.37%) | | 0.31 (0.15–0.61) |
| 4,256 | Semaglutide | TZD | <10 (<0.24%) | 20 (0.47%) | | 0.31 (0.13–0.74) |
| 9,448 | Semaglutide | Other GLP–1RAs | 11 (0.12%) | 18 (0.19%) | | 0.59 (0.28–1.25) |

Hazard Ratio (HR)

0.10  0.20  0.40  0.70  2.0  3.00  5.00  8.00